JP7036594B2 - Ｂｒａｆ陽性癌を患っている患者を、ｂｒａｆ阻害剤に対する非レスポンダーであると及びｍａｐｋ／ｅｒｋ阻害剤に対するレスポンダーであると同定する手段及び方法 - Google Patents

Ｂｒａｆ陽性癌を患っている患者を、ｂｒａｆ阻害剤に対する非レスポンダーであると及びｍａｐｋ／ｅｒｋ阻害剤に対するレスポンダーであると同定する手段及び方法 Download PDF

Info

Publication number
JP7036594B2
JP7036594B2 JP2017522732A JP2017522732A JP7036594B2 JP 7036594 B2 JP7036594 B2 JP 7036594B2 JP 2017522732 A JP2017522732 A JP 2017522732A JP 2017522732 A JP2017522732 A JP 2017522732A JP 7036594 B2 JP7036594 B2 JP 7036594B2
Authority
JP
Japan
Prior art keywords
braf
seq
mutation
nras
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017522732A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529094A5 (https=
JP2017529094A (ja
Inventor
パウル レベック ミッチェル
ドゥンマー ラインハルト
ビドマー ダニエル
イネケ ゲールトチェス ラアイマケルス マリーケ
Original Assignee
ウニベルジテート チューリッヒ プロレクトラット エムエンベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51210291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7036594(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ウニベルジテート チューリッヒ プロレクトラット エムエンベー filed Critical ウニベルジテート チューリッヒ プロレクトラット エムエンベー
Publication of JP2017529094A publication Critical patent/JP2017529094A/ja
Publication of JP2017529094A5 publication Critical patent/JP2017529094A5/ja
Application granted granted Critical
Publication of JP7036594B2 publication Critical patent/JP7036594B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2017522732A 2014-07-14 2015-07-13 Ｂｒａｆ陽性癌を患っている患者を、ｂｒａｆ阻害剤に対する非レスポンダーであると及びｍａｐｋ／ｅｒｋ阻害剤に対するレスポンダーであると同定する手段及び方法 Active JP7036594B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14176944 2014-07-14
EP14176944.8 2014-07-14
PCT/EP2015/065986 WO2016008853A1 (en) 2014-07-14 2015-07-13 Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor

Publications (3)

Publication Number Publication Date
JP2017529094A JP2017529094A (ja) 2017-10-05
JP2017529094A5 JP2017529094A5 (https=) 2018-07-05
JP7036594B2 true JP7036594B2 (ja) 2022-03-15

Family

ID=51210291

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017522732A Active JP7036594B2 (ja) 2014-07-14 2015-07-13 Ｂｒａｆ陽性癌を患っている患者を、ｂｒａｆ阻害剤に対する非レスポンダーであると及びｍａｐｋ／ｅｒｋ阻害剤に対するレスポンダーであると同定する手段及び方法

Country Status (7)

Country Link
US (1) US20190194757A1 (https=)
EP (1) EP3169797B2 (https=)
JP (1) JP7036594B2 (https=)
CN (1) CN107148481A (https=)
CA (1) CA2953732C (https=)
ES (1) ES2751925T5 (https=)
WO (1) WO2016008853A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
AU2018269982B2 (en) * 2017-05-16 2024-06-13 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical BRAF mutations
CN112795647B (zh) * 2019-11-14 2022-08-16 北京肿瘤医院(北京大学肿瘤医院) 一种肿瘤标志物及其应用
CN111020033A (zh) * 2019-12-24 2020-04-17 中山大学达安基因股份有限公司 多重检测braf基因突变的试剂盒及方法
CN118043654A (zh) * 2021-06-23 2024-05-14 皇家墨尔本理工大学 用于检测核酸的电导式传感器及其检测方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068562A2 (en) 2010-11-19 2012-05-24 The Regents Of The University Of California Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
JP2013543008A (ja) 2010-11-19 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド Ｂｒａｆ阻害剤による治療方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120252015A1 (en) * 2011-02-18 2012-10-04 Bio-Rad Laboratories Methods and compositions for detecting genetic material
EP3249053A1 (en) * 2009-03-27 2017-11-29 Life Technologies Corporation Methods, compositions, and kits for detecting allelic variants
US20130315934A1 (en) * 2010-10-28 2013-11-28 Yale University Methods and Compositions for Assessing and Treating Cancer
US20130217710A1 (en) 2010-11-05 2013-08-22 Glaxosmithkline Intellectual Property (No.2) Limited Methods for treating cancer
WO2014009319A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Indolinone derivatives anticancer compounds
WO2014009318A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh 3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer
CA2886397A1 (en) * 2012-09-26 2014-04-03 Insight Genetics, Inc. Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068562A2 (en) 2010-11-19 2012-05-24 The Regents Of The University Of California Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
JP2013543008A (ja) 2010-11-19 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド Ｂｒａｆ阻害剤による治療方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Ｃａｎｃｅｒ Ｒｅｓ．，２００３年，Ｖｏｌ．６３，Ｎｏ．１５，ｐｐ．４５６１－４５６７
Ｊ．Ｍｏｌ．Ｄｉａｇｎ．，２０１３年，Ｖｏｌ．１５，Ｎｏ．１，ｐｐ．９４－１００
ＭＯＬＥＣＵＬＡＲ ＣＡＮＣＥＲ ＴＨＥＲＡＰＥＵＴＩＣＳ，２０１２年４月１日，Ｖｏｌ．１１，Ｎｏ．４，ｐｐ．９０９－９２０
Ｎａｔｕｒｅ，２０１０年，Ｖｏｌ．４６８，Ｎｏ．７３２６，ｐｐ．９７３－９７７

Also Published As

Publication number Publication date
ES2751925T3 (es) 2020-04-02
EP3169797B1 (en) 2019-08-21
EP3169797B2 (en) 2025-02-19
ES2751925T5 (en) 2025-05-13
JP2017529094A (ja) 2017-10-05
US20190194757A1 (en) 2019-06-27
CA2953732A1 (en) 2016-01-21
EP3169797A1 (en) 2017-05-24
WO2016008853A1 (en) 2016-01-21
CN107148481A (zh) 2017-09-08
CA2953732C (en) 2023-09-26

Similar Documents

Publication Publication Date Title
Lignitto et al. Nrf2 activation promotes lung cancer metastasis by inhibiting the degradation of Bach1
Yu et al. Whole-exome sequencing identifies rare, functional CFH variants in families with macular degeneration
Atwood et al. Smoothened variants explain the majority of drug resistance in basal cell carcinoma
Durinikova et al. Targeting the DNA damage response pathways and replication stress in colorectal cancer
Carvalho et al. Lack of microRNA‐101 causes E‐cadherin functional deregulation through EZH2 up‐regulation in intestinal gastric cancer
Erdem-Eraslan et al. Identification of patients with recurrent glioblastoma who may benefit from combined bevacizumab and CCNU therapy: a report from the BELOB trial
Nguyen et al. The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution
WO2020219721A1 (en) Compositions and methods characterizing metastasis
Cho et al. High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients
Lin et al. Genetic interactions reveal distinct biological and therapeutic implications in breast cancer
Barbieri et al. Molecular genetics of prostate cancer: emerging appreciation of genetic complexity
JP7036594B2 (ja) Ｂｒａｆ陽性癌を患っている患者を、ｂｒａｆ阻害剤に対する非レスポンダーであると及びｍａｐｋ／ｅｒｋ阻害剤に対するレスポンダーであると同定する手段及び方法
US11685953B2 (en) Biomarkers and methods of treating cancer
Zhong et al. Genetic variations in TERT‐CLPTM1L locus are associated with risk of lung cancer in Chinese population
Flynn et al. Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles
Wu et al. Characterization of the pleural microenvironment niche and cancer transition using single-cell RNA sequencing in EGFR-mutated lung cancer
US20210238696A1 (en) Biomarkers for the Identification of Prostate Cancer and Methods of Use
Van Goubergen et al. Targeting the CLK 2/SRSF 9 splicing axis in prostate cancer leads to decreased ARV 7 expression
Chong et al. Molecular differentiation between complete and incomplete responders to neoadjuvant therapy in rectal cancer
Chen et al. Gene expression profiling and the isocitrate dehydrogenase mutational landscape of temozolomide‑resistant glioblastoma
WO2020005068A2 (en) Gene signatures and method for predicting response to pd-1 antagonists and ctla-4 antagonists, and combination thereof
Tothill et al. Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles
Daneshmand-Parsa et al. Introduction of LPIN1 as a potential diagnostic and prognostic biomarker for gastric cancer via integrative bioinformatics analysis of a competing endogenous RNA network and experimental validation
Wang et al. MMP11 predicts colorectal cancer outcomes and its inhibitor RXP03 exerts anti-tumor effects via apoptosis activation
US20240026458A1 (en) Method for Determining Sensitivity to an Antineoplastic Agent

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20170113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180523

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190702

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200507

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200512

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200611

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200616

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200904

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200908

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210216

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210831

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20211026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211201

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20211221

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220201

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220303

R150 Certificate of patent or registration of utility model

Ref document number: 7036594

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250